Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 2von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Liposarcoma 1Leiomyosarcoma 1Hamartoma Syndrome, Multiple 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Bone Neoplasms 1Autistic Disorder 1Astrocytoma 1

Interventions

lenvatinib 1fludarabine 1aldesleukin 1Nivolumab 1Masks 1Ipilimumab 1Gemcitabine 1Everolimus 1Cyclophosphamide 1CTLA-4 Antigen 1Behavioral Sciences 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × Everolimus × 30 days × Clear all
NCT07619950 2026-06-02

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma

Yonsei University

Phase 2 Not yet recruiting
94 enrolled
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡